Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q05932

UPID:
FOLC_HUMAN

ALTERNATIVE NAMES:
Folylpoly-gamma-glutamate synthetase; Tetrahydrofolylpolyglutamate synthase

ALTERNATIVE UPACC:
Q05932; B3KPW4; B7Z2Z3; F5H0K6; Q5JU19; Q5JU22; Q6P2P6

BACKGROUND:
Folylpolyglutamate synthase, a key mitochondrial enzyme, is instrumental in the metabolism of folates into polyglutamate forms. This process is essential for the intracellular retention and concentration of folate cofactors, vital for the one-carbon transfer reactions necessary for the biosynthesis of purines, pyrimidines, and amino acids. The enzyme's ability to metabolize methotrexate (MTX) to polyglutamates highlights its significance in cellular functions.

THERAPEUTIC SIGNIFICANCE:
Exploring the functionalities of Folylpolyglutamate synthase unveils potential avenues for the development of novel therapeutic interventions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.